Philippe Duneton11 February 2009
This presentation is the property of its rightful owner.
Sponsored Links
1 / 13

Philippe Duneton11 February 2009 Deputy Executive Secretary PowerPoint PPT Presentation


  • 100 Views
  • Uploaded on
  • Presentation posted in: General

Philippe Duneton11 February 2009 Deputy Executive Secretary. 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines. Addressing Global HIV/AIDS Challanges. Today 9.5 million people in need of treatment

Download Presentation

Philippe Duneton11 February 2009 Deputy Executive Secretary

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Philippe duneton 11 february 2009 deputy executive secretary

Philippe Duneton11 February 2009

Deputy Executive Secretary

5th Consultative Stakeholder Meeting

UN Prequalification of Diagnostics, Medicines & Vaccines


Philippe duneton 11 february 2009 deputy executive secretary

Addressing Global HIV/AIDS Challanges

  • Today 9.5 million people in need of treatment

  • 4 million people on HIV/AIDS treatment and rapid expansion of access required

  • Only 42% of needs currently being met of which 276,000 children (38% coverage)

  • New treatment guidelines (CD4 <350) = more people in treatment

  • Financial crisis: funding is not increasing

  • Key challenge: keep HIV/AIDS on top of the global agenda


Philippe duneton 11 february 2009 deputy executive secretary

UNITAID Strategy: Portfolio 2006-2012

Time 2006 2009 2010 2011 2012

New treatments/regimens (FDCs)

2nd line treatments

HIV/AIDS

Paediatric treatments (scaling up/transition)

PMTCT(Lessons Learnt)

Viral Load

Prevention commodities?

Malaria

LLIN

ACT– increase access

Rapid tests?

New 1st line treatments? (2mths)

1st line treatments

Tuberculosis

MDR- TB treatments

MDR- TB tests

Co-morbidities

HCV?

Today


Philippe duneton 11 february 2009 deputy executive secretary

Scope of work in the Pharmaceutical value chain


Philippe duneton 11 february 2009 deputy executive secretary

Lower prices of treatments

Enable more patients to be treated (e.g. with the same budget)

Facilitate government adoption of improved medicines

Formulation-related benefits

FDCs:

Facilitate adherence, reduced risk of resistance, simplified supply chains

Paediatric formulations:

Improved quality treatment for infants and children, reduced shipment costs for solids (vs. liquids)

Heat-stable:

Enabled use in resource-poor settings

Seeking efficient use of funds and

public health benefits


Philippe duneton 11 february 2009 deputy executive secretary

UNITAID Strategy 2010-2012

Goal

Objectives

Mission

UNITAID’s mission is to contribute to scaling up access to treatment for HIV/AIDS, malaria and tuberculosis, primarily for people in low-income countries, by leveraging price reductions for quality diagnostics and medicines and accelerating the pace at which these are made available.

[Constitution]

Using innovative, global market based approaches to improve public health by increasing access to quality products to treat, diagnose and prevent HIV/AIDS, tuberculosis, malaria and related co-morbidities in developing countries.

  • To increase access to efficacious, safe and assured quality products that address Public Health problems

  • To support adaptation of products targeting specific populations

  • To ensure affordable and sustainably priced products

  • To assure availability in sufficient quantities and timely delivery to patients


Philippe duneton 11 february 2009 deputy executive secretary

Scope on Diseases and Products

Strategy 2010-2012

  • Products to treat and diagnose HIV/AIDS, TB, and malaria

  • Targeted prevention products that align with UNITAID goals and objectives

  • Products for co-morbiditieswhere:

    • burden of disease is high

    • efficacious and cost-effectiveness products are available

    • opportunity for positive public health & market impact is attainable


Philippe duneton 11 february 2009 deputy executive secretary

Boosting WHO Quality Assurance Programmes

Additional support and multi-year

commitment to

Accelerate the pace at which priority HIV/AIDS, malaria and TB medicines are prequalified

Increase the number of QA laboratories in developing countries

Control the quality of strategic medicines close to treatment centers

2006-2012: US$ 47 million approved


Philippe duneton 11 february 2009 deputy executive secretary

Support to WHO QA Diagnostic Programme

Prequalify priority HIV/AIDS and malaria diagnostics

Address costs concerns

Build or strengthen national regulatory capacity

2009-2013 support: US$ 7,5 million approved

Boosting WHO Quality Assurance Programmes


Philippe duneton 11 february 2009 deputy executive secretary

Patent Pool: innovation and better products

  • Diversifying supply sources to reduce prices

  • Expanding generic market size to reduce prices & expand access

  • Facilitating the development of improved formulations (e.g. Fixed Dose Combinations (FDCs), paediatric and heat-stable formulations)

  • Increasing legal certainty for generic companies and patent-holders

  • Reducing transaction costs for licensing agreements (e.g. FDCs)


Philippe duneton 11 february 2009 deputy executive secretary

Partnership: Looking ahead

  • Reduced prequalification timeline for priority medicines:

    • Quality assured atazanavir/rto achieve second line therapy objectives

    • Quality assurance timing in line with theUNITAID project cycle

      • Second Line ARV transition: 2010-2011

      • Paediatric HIV/AIDS transition: 2011-2012?

    • Increased number ofinnovative FDCs, heat-stable and paediatric formulationsfacilitated by the Patent Pool

      • Key role in providing technical support to manufacturers

      • Address new products not based on innovators

    • Quality APIs to boost global generic supply

    • Strengthen capacity of NRAs

    • Access to prequalified HIV and malaria diagnostics


Philippe duneton 11 february 2009 deputy executive secretary

UNITAID Strategy: Portfolio 2006-2012

Time 2006 2009 2010 2011 2012

New treatments/regimens (FDCs)

2nd line treatments

HIV/AIDS

Paediatric treatments (scaling up/transition)

PMTCT(Lessons Learnt)

Viral Load

Prevention commodities?

Malaria

LLIN

ACT– increase access

Rapid tests?

New 1st line treatments? (2mths)

1st line treatments

Tuberculosis

MDR- TB treatments

MDR- TB tests

Co-morbidities

HCV?

Today


  • Login